Osteopenia Articles

Articles

  • A Prospective, Observational Study of Osteoporosis in Men.

    The number of men afflicted with osteoporosis is unknown.

    This study aims to determine the prevalence of osteoporosis in men.

    This was a prospective, observational study.

    A total of 200 male attendants of patients attending endocrine outpatient department and who were >55 years were recruited for the study.

    Published April 22, 2018
  • Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.

    Nephrolithiasis is a risk factor for Osteopenia and osteoporosis. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate bone remodeling and osteoclastogenesis.

    Published July 17, 2018
  • Zoledronate.

    Zoledronate is the most potent and most long-acting bisphosphonate in clinical use, and is administered as an intravenous infusion. Its major uses are in osteoporosis, Paget's disease, and in myeloma and cancers to reduce adverse skeletal related events (SREs).

    Published May 8, 2020